ImmunoCellular Therapeutics (OTCBB: IMUC.OB - News) today announced that it has entered into an agreement with The Johns Hopkins University (JHU) under which JHU has granted the Company an exclusive, worldwide license to intellectual property surrounding the tumor-associated antigen mesothelin, which is highly expressed in pancreatic cancer, ovarian cancer and mesothelioma. The terms of the agreement were not disclosed.
The Company will employ this intellectual property in the development and commercialization of ICT-140, a multivalent, dendritic cell-based vaccine for the treatment of ovarian cancer, one of multiple tumor types in which mesothelin is over-expressed. ICT-140 is designed to target cancer stem cells as well as daughter cells in ovarian cancer by targeting multiple different antigens including mesothelin, Her-2/neu, IL-13Rα2 and several other undisclosed antigens.
Excellent news. Arguably, JH is the best med school in the country. I see this as a ringing endorsement for IMUC's technology. On just my opinion alone, this stock should be up a dollar on this news ( this was released Mon. - no?).
i'd love to see it up $1,on the news but noway thats going to happen,yes real good news,but not great news,great news would be the FDA giving approval to one of its drugs,then you would see the stock price rocket.
Shows that they are committed to pipeline development and expanding their intellectual property. Crossing all the T's and dotting all the i's early on for them to be able to move on to the next step. Great move